Physician profile
Mark Harold Petry
NPI 1487668034
$1,013.90
in general payments reported to CMS, 2019-2025
30 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.27 · 2020: $24.27 · 2021: $271 · 2022: $110 · 2023: $144 · 2024: $198 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120.30 | 2022-2025 | Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $96.49 | 2021-2025 | Keveyis |
| Pfizer INC. | $86.07 | 2019-2024 | |
| Amgen INC. | $82.47 | 2021-2024 | Repatha, Otezla |
| Abbvie INC. | $74.19 | 2021-2025 | |
| Eisai INC. | $49.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.58 | 2022-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $47.49 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $45.77 | 2024-2025 | Zenpep |
| Roche Diagnostics Corporation | $40.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.86 | 2023 | Spiriva Respimat |
| Novo Nordisk INC | $25.25 | 2021-2025 | Wegovy |
| Advanced Respiratory, INC | $24.61 | 2021 | |
| Edwards Lifesciences Corporation | $20.29 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Viatris Specialty LLC | $18.89 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.70 | 2022 | |
| Medtronic, INC. | $16.78 | 2024 | Intellis Adaptivestim |
| Circassia INC. | $15.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.17 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $14.96 | 2021 | |
| Gilead Sciences, INC. | $14.55 | 2024 | |
| Horizon Therapeutics Plc | $14.36 | 2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.46 | 2025 | Rexulti |
| Morphosys, US INC. | $13.30 | 2021 | |
| Dermira, INC. | $12.96 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.26 | 2021 | |
| Allergan, INC. | $12.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.08 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $7.72 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Petry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.